tetano
Editor, Senior Moderator
Emerg Microbes Infect
. 2022 Feb 18;1-11.
doi: 10.1080/22221751.2022.2044271. Online ahead of print.
Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant
Xiaoling Yu[SUP] 1 [/SUP], Xiangrong Qi[SUP] 1 [/SUP], Yu Cao[SUP] 2 [/SUP], Peiyao Li[SUP] 1 [/SUP], Li Lu[SUP] 3 [/SUP], Pingping Wang[SUP] 1 [/SUP], Yuchen Feng[SUP] 1 [/SUP], Jie Yang[SUP] 1 [/SUP], Huihui Wei[SUP] 1 [/SUP], Lixian Guo[SUP] 1 [/SUP], Mingyue Sun[SUP] 1 [/SUP], Qiang Liu[SUP] 1 [/SUP], Jing Lv[SUP] 1 [/SUP], Yingmei Feng[SUP] 2 [/SUP]
Affiliations
Abstract
The immunity potency upon natural infection or vaccination is the main concern for the vaccine strategy of severe acute respiratory syndrome coronavirus 2（SARS COV-2 variant）, especially the recently reported Omicron variant (B.1.1.529). In this study, 200 recipients immunized with three doses of a COVID-19-inactivated vaccine were enrolled, whose serum samples were collected within 2 months after the third immunization. The neutralizing activity of sera against the pseudotyped Omicron variant, prototype, and Delta variant was determined. Our results demonstrated that the positive neutralization activity was 95.5% for the Omicron variant, 99.5% for the prototype, and 98.5% for the Delta variant. The geometric mean titers （GMT） for the Omicron variant was 49 and maintained sustained immune levels for 2 months, which decreased by 4.9-fold and 3.0-fold compared with the prototype (GMT, 239) and Delta variant (GMT, 148), respectively. In summary, our study demonstrated that three doses of a COVID-19-inactivated vaccine effectively yielded potent cross-neutralizing activity against the Omicron variant at 2 months after the third vaccination.
Keywords: Omicron variant; SARSCoV-2; neutralizing antibody; vaccine.
. 2022 Feb 18;1-11.
doi: 10.1080/22221751.2022.2044271. Online ahead of print.
Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant
Xiaoling Yu[SUP] 1 [/SUP], Xiangrong Qi[SUP] 1 [/SUP], Yu Cao[SUP] 2 [/SUP], Peiyao Li[SUP] 1 [/SUP], Li Lu[SUP] 3 [/SUP], Pingping Wang[SUP] 1 [/SUP], Yuchen Feng[SUP] 1 [/SUP], Jie Yang[SUP] 1 [/SUP], Huihui Wei[SUP] 1 [/SUP], Lixian Guo[SUP] 1 [/SUP], Mingyue Sun[SUP] 1 [/SUP], Qiang Liu[SUP] 1 [/SUP], Jing Lv[SUP] 1 [/SUP], Yingmei Feng[SUP] 2 [/SUP]
Affiliations
- PMID: 35176972
- DOI: 10.1080/22221751.2022.2044271
Abstract
The immunity potency upon natural infection or vaccination is the main concern for the vaccine strategy of severe acute respiratory syndrome coronavirus 2（SARS COV-2 variant）, especially the recently reported Omicron variant (B.1.1.529). In this study, 200 recipients immunized with three doses of a COVID-19-inactivated vaccine were enrolled, whose serum samples were collected within 2 months after the third immunization. The neutralizing activity of sera against the pseudotyped Omicron variant, prototype, and Delta variant was determined. Our results demonstrated that the positive neutralization activity was 95.5% for the Omicron variant, 99.5% for the prototype, and 98.5% for the Delta variant. The geometric mean titers （GMT） for the Omicron variant was 49 and maintained sustained immune levels for 2 months, which decreased by 4.9-fold and 3.0-fold compared with the prototype (GMT, 239) and Delta variant (GMT, 148), respectively. In summary, our study demonstrated that three doses of a COVID-19-inactivated vaccine effectively yielded potent cross-neutralizing activity against the Omicron variant at 2 months after the third vaccination.
Keywords: Omicron variant; SARSCoV-2; neutralizing antibody; vaccine.